EdwardHauder.com

Looking at the proxy statements that were filed last week (8/31/2009-9/6/2009), here are the new plans and amendments that I found (Company, plan name, (date proxy filed) and [share request as a percent of Common Shares Outstanding as of the record date/disclosed in the proxy or 10-K or latest 10-Q]):

New Equity Compensation Plan Proposals

• Acies Corp., 2009 Stock Incentive Plan (9/3/2009) [13.5%]
• Cryoport, Inc., 2009 Stock Incentive Plan (9/1/2009) [25.7%]
• Commonwealth Biotechnologies Inc., 2009 Stock Incentive Plan (9/1/2009) [12.2%]
• Conolog Corp., 2009 Stock Incentive Plan (8/31/2009) [43.4%]

New Equity Compensation Plan Amendment Proposals

• Cell Therapeutics Inc., 2007 Equity Incentive Plan (9/4/2009) [8.3%]
• API Nanotronics Corp., 2006 Equity Incentive Plan (9/4/2009) [10.2%]
• Cree Inc., 2004 Long-Term Incentive Compensation Plan (9/4/2009) [3.3%]
• Briggs & Stratton Corp., Incentive Compensation Plan (amended & restated) (9/3/2009) [13.6%]
• Joe’s Jeans Inc., 2004 Stock Incentive Plan (8/31/2009) [6.6%]

Conolog Corp.’s proposed plan is not only notable for the significant dilution it represents, but it is quite possibly the shortest equity compensation plan I’ve ever read — all four articles of it.

[print_link]